Back to search results

Brain Health in Breast Cancer Survivors on Endocrine Therapy

This observational study is looking at how endocrine therapy (ET), a common treatment for hormone receptor-positive breast cancer, might affect brain health and thinking skills (cognition). ET works by lowering estrogen, which can also impact the brain. Researchers want to understand why some studies show mixed results about ET's effects on cognition. They will compare brain activity and cognitive function between breast cancer survivors receiving ET and healthy women of similar age, race, and education. You may be able to join if you are a woman between 35 and 65 years old, fluent in English, and have good vision and hearing. The study aims to enroll 120 participants.

Study design
This is an observational study comparing breast cancer survivors on endocrine therapy with healthy controls. It plans to include 120 participants.
What's involved
The study will measure brain activity and cognitive function on Day 1.
Compensation
Not stated in the trial record.
Follow-up
Brain activity and cognitive function will be measured on Day 1.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04297020

Brain Health in Breast Cancer Survivors

Recruiting
Not specifiedAges 35–65Observational
Jonsson Comprehensive Cancer Center
~120 participants
Updated 2026-07-07 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Brain activity comparison between breast cancer survivors undergoing endocrine therapy and healthy matched control subject.
Measured over Day 1
+1 more outcome measured

Conditions

Cognitive Impairment
Cognitive Function

Explore related trials

Breast Carcinoma

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Kathleen Van Dyk, PhD · PRINCIPAL_INVESTIGATOR · University of California at Los Angeles

Who to contact

Kathleen Van Dyk, PhD
[email protected]
310 825-2719
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 35-65
Fluent in English
Adequate vision/hearing to complete testing

Exclusion

History of major or mild neurocognitive disorder or dementia
Diagnosis of major neurological condition (e.g., epilepsy, Parkinson's Disease, stroke)
Diagnosis of a major psychiatric disorder (e.g., bipolar disorder, schizophrenia)
Untreated/unstable unipolar depression or anxiety
Prior history of cancer or chemotherapy (for controls, any history)
History of a learning disorder
History of head injury with loss of consciousness \>20 minutes
History of salpingo-oophorectomy or hysterectomy
A cardiac pacemaker
Implanted electronic device
Claustrophobia
Currently pregnant
Orbital metal implant or other metallic foreign bodies

What this trial measures

  • Brain activity comparison between breast cancer survivors undergoing endocrine therapy and healthy matched control subject.Day 1

    To compare brain activity using fMRI during a working memory task between breast cancer survivors on ET and matched healthy controls, and examine the interaction of menopausal status.

  • Cognitive function comparison between breast cancer survivors undergoing endocrine therapy and healthy matched control subject.Day 1

    To compare cognitive function between breast cancer survivors on ET and matched healthy controls, and examine the interaction of menopausal status.